Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadolinium-dtpa
Drug ID BADD_D00990
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status approved
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707; D08006
MeSH ID D019786
PubChem ID 6857474
TTD Drug ID D0RQ2W
NDC Product Code Not Available
UNII Not Available
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C14H20GdN3O10
CAS Registry Number 80529-93-7
SMILES C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pallor08.01.03.032; 24.03.04.001; 23.03.03.031--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pharyngeal oedema22.04.05.003; 10.01.05.016; 23.04.01.016--Not Available
Phlebitis24.12.03.004; 12.02.01.002--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Rash23.03.13.001--Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Renal failure20.01.03.005--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory distress22.02.01.012--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Sneezing22.12.03.024--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Surgery25.01.02.003--Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Teething07.09.05.005--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tremor17.01.06.002--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages